LENZ vs. MLTX, MRUS, BEAM, IBRX, ARWR, HCM, EWTX, MIRM, AMRX, and KYMR
Should you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include MoonLake Immunotherapeutics (MLTX), Merus (MRUS), Beam Therapeutics (BEAM), ImmunityBio (IBRX), Arrowhead Pharmaceuticals (ARWR), HUTCHMED (HCM), Edgewise Therapeutics (EWTX), Mirum Pharmaceuticals (MIRM), Amneal Pharmaceuticals (AMRX), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.
LENZ Therapeutics vs.
MoonLake Immunotherapeutics (NASDAQ:MLTX) and LENZ Therapeutics (NASDAQ:LENZ) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, community ranking, dividends, analyst recommendations, institutional ownership and media sentiment.
MoonLake Immunotherapeutics received 54 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 81.01% of users gave MoonLake Immunotherapeutics an outperform vote.
93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 38.4% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
MoonLake Immunotherapeutics presently has a consensus target price of $85.50, suggesting a potential upside of 102.22%. LENZ Therapeutics has a consensus target price of $35.40, suggesting a potential upside of 50.70%. Given MoonLake Immunotherapeutics' higher possible upside, research analysts clearly believe MoonLake Immunotherapeutics is more favorable than LENZ Therapeutics.
MoonLake Immunotherapeutics' return on equity of -15.54% beat LENZ Therapeutics' return on equity.
In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than LENZ Therapeutics. MarketBeat recorded 4 mentions for MoonLake Immunotherapeutics and 2 mentions for LENZ Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.86 beat LENZ Therapeutics' score of 0.63 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.
MoonLake Immunotherapeutics has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.
Summary
MoonLake Immunotherapeutics beats LENZ Therapeutics on 9 of the 12 factors compared between the two stocks.
Get LENZ Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LENZ Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LENZ) was last updated on 2/22/2025 by MarketBeat.com Staff
Free LENZ Stock Alerts